mc2-CMX

Stage of Development

Proof of Concept – Animal Model

Vaccine Platform

Mycobacterial – Live Attenuated

Candidate Overview

The mc2-CMX vaccine is a live attenuated vaccine that was developed using M. tuberculosis Ag85, MPT-51 and HSP-x to generate a fusion protein called CMX. The nucleotide sequences corresponding to epitopes 85 to 159 bp of Ag85C and 91 to 112 bp of MPT51 and HSP-x. The gene sequence was inserted in the genome of Mycobacterium smegmatis. This vaccine is formulated in PBS Tween containing 10-7 CFU.

Sponsor / Lead Developer: Universidade Federal de Goiás

Primary Indication: Prevention of TB disease

Target Population(s): Adolescents, Adults, People with Mtb infection, People without Mtb infection, and To be determined

Target Route of Administration: Subcutaneous

Immune tissue localization: Lung, Lymph node, and Spleen

Immunological responses: T-cell

Preclinical Animal Models: Cow and Mouse

Intended to elicit trained immunity: No

Additional Immunologic Response Information

	HYPOTHESIZED	DEMONSTRATED
Immune Response		T-cell
T-cell phenotype	TH17 TH1 Neutrophils	CD4 CD8 Natural Killer (NK)
T-cell functional profile	Polycytotoxicity	IFN-γ TNF-α IL-17 Mycobacterial growth inhibition
Preferential immune tissue localization	Spleen	Lung Lymph node Skin
Trained immunity	No